Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome

We aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in young people with Down syndrome (DS), and to compare their humoral immune response with those of the healthy controls (HC). Individuals with DS and HC received the BNT162b2 vaccine. Longitudinal blood samples were collecte...

Descripción completa

Detalles Bibliográficos
Autores principales: Valentini, Diletta, Cotugno, Nicola, Scoppola, Vittorio, Di Camillo, Chiara, Colagrossi, Luna, Manno, Emma Concetta, Perno, Carlo Federico, Russo, Cristina, Palma, Paolo, Rossi, Paolo, Villani, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836979/
https://www.ncbi.nlm.nih.gov/pubmed/35160144
http://dx.doi.org/10.3390/jcm11030694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836979/
https://www.ncbi.nlm.nih.gov/pubmed/35160144
http://dx.doi.org/10.3390/jcm11030694

Ejemplares similares